# Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

> **NCT00863655** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 724 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Exemestane
- **DRUG:** Everolimus Placebo

## Key facts

- **NCT ID:** NCT00863655
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-03
- **Primary completion:** 2014-12-04
- **Final completion:** 2014-12-04
- **Target enrollment:** 724 (ACTUAL)
- **Last updated:** 2017-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00863655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00863655, "Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00863655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*